Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study-Reference-Cited by-同舟云学术

Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study

Published:2017-02-24 Issue:10 Volume:64 Page:e26491
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Moritake Hiroshi¹²,Tanaka Shiro³,Nakayama Hideki⁴,Miyamura Takako⁵,Iwamoto Shotaro⁶,Shimada Akira⁷,Terui Kiminori⁸,Saito Akiko²,Shiba Norio⁹,Hayashi Yasuhide¹⁰,Tomizawa Daisuke¹¹,Taga Takashi¹²,Goto Hiroaki¹³,Hasegawa Daisuke¹⁴,Horibe Keizo²,Mizutani Shuki¹⁵,Adachi Souichi¹⁶

Affiliation:

1. Division of Pediatrics; Faculty of Medicine; University of Miyazaki; Miyazaki Japan

2. Clinical Research Center; Nagoya Medical Center; National Hospital Organization; Nagoya Japan

3. Department of Pharmacoepidemiology; Graduate School of Medicine and Public Health; Kyoto University; Kyoto Japan

4. Department of Pediatrics; National Hospital Organization; Fukuoka-Higashi Medical Center; Fukuoka Japan

5. Department of Pediatrics; Osaka University School of Medicine; Osaka Japan

6. Department of Pediatrics; Mie University Graduate School of Medicine; Tsu Japan

7. Department of Pediatrics; Okayama University; Okayama Japan

8. Department of Pediatrics; Hirosaki University Graduate School of Medicine; Hirosaki Japan

9. Department of Pediatrics; Gunma University Graduate School of Medicine; Maebashi Japan

10. Department of Hematology/Oncology; Gunma Children's Medical Center; Shibukawa Japan

11. Division of Leukemia and Lymphoma; National Center for Child Health and Development; Children's Cancer Center; Tokyo Japan

12. Department of Pediatrics; Shiga University of Medical Science; Otsu Japan

13. Division of Hemato-Oncology/Regenerative Medicine; Kanagawa Children's Medical Center; Yokohama Japan

14. Department of Pediatrics; St. Luke's International Hospital; Tokyo Japan

15. Department of Pediatrics and Developmental Biology; Tokyo Medical and Dental University; Tokyo Japan

16. Department of Human Health Sciences; Kyoto University; Kyoto Japan

Funder

Miyazaki University Hospital

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference9 articles.

1. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial;Rubnitz;Lancet Oncol.,2010

2. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12;Harrison;J Clin Oncol,2010

3. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98;Neuhoff;J Clin Oncol,2010

4. Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children;Tomizawa;Leukemia,2013

5. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group;Kaspers;J Clin Oncol,2013

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16);BMC Cancer;2023-05-25

2. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML‐05R study;Pediatric Blood & Cancer;2020-09-29

3. Natural HDAC‐1/8 inhibitor baicalein exerts therapeutic effect in CBF‐AML;Clinical and Translational Medicine;2020-08

4. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia;Journal of Pediatric Hematology/Oncology;2019-10-29

5. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia;Pediatrics International;2017-10